Ube3a/E6AP is involved in a subset of MeCP2 functions

Biochemical and Biophysical Research Communications

Volumn 437, Issue 1, 2013, Pages 67-73

  Kim, Soeun ^a   Chahrour, Maria ^b,c   Ben Shachar, Shay ^b,d   Lim, Janghoo ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Angelman syndrome; MeCP2; Rett syndrome; Ube3a E6AP

Indexed keywords

E6 ASSOCIATED PROTEIN; METHYL CPG BINDING PROTEIN 2; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DROSOPHILA; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANGELMAN SYNDROME; MECP2; RETT SYNDROME; UBE3A/E6AP;

ANIMALS; CO-REPRESSOR PROTEINS; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; EYE; FEMALE; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; MALE; METHYL-CPG-BINDING PROTEIN 2; MICE; MICE, TRANSGENIC; PHENOTYPE; PROTEIN BINDING; UBIQUITIN-PROTEIN LIGASES;

HUMAN PAPILLOMAVIRUS; MUS;

EID: 84880514835     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.036     Document Type: Article

References (30)

1. Amir R.E., Van den Veyver I.B., Wan M., Tran C.Q., Francke U., Zoghbi H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 1999, 23:185-188.
2. Clayton-Smith J., Laan L. Angelman syndrome: a review of the clinical and genetic aspects. J. Med. Genet. 2003, 40:87-95.
3. Kishino T., Lalande M., Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat. Genet. 1997, 15:70-73.
4. Matsuura T., Sutcliffe J.S., Fang P., Galjaard R.J., Jiang Y.H., Benton C.S., Rommens J.M., Beaudet A.L. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat. Genet. 1997, 15:74-77.
5. Huibregtse J.M., Scheffner M., Beaudenon S., Howley P.M. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl. Acad. Sci. USA 1995, 92:2563-2567.
6. Ariani F., Mari F., Pescucci C., Longo I., Bruttini M., Meloni I., Hayek G., Rocchi R., Zappella M., Renieri A. Real-time quantitative PCR as a routine method for screening large rearrangements in Rett syndrome: report of one case of MECP2 deletion and one case of MECP2 duplication. Hum. Mutat. 2004, 24:172-177.
7. Cook E.H., Lindgren V., Leventhal B.L., Courchesne R., Lincoln A., Shulman C., Lord C., Courchesne E. Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. Am. J. Hum. Genet. 1997, 60:928-934.
8. Nan X., Campoy F.J., Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997, 88:471-481.
9. Young J.I., Hong E.P., Castle J.C., Crespo-Barreto J., Bowman A.B., Rose M.F., Kang D., Richman R., Johnson J.M., Berget S., Zoghbi H.Y. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc. Natl. Acad. Sci. USA 2005, 102:17551-17558.
10. Chahrour M., Jung S.Y., Shaw C., Zhou X., Wong S.T., Qin J., Zoghbi H.Y. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008, 320:1224-1229.
11. Long S.W., Ooi J.Y., Yau P.M., Jones P.L. A brain-derived MeCP2 complex supports a role for MeCP2 in RNA processing. Biosci. Rep. 2011, 31:333-343.
12. Harikrishnan K.N., Chow M.Z., Baker E.K., Pal S., Bassal S., Brasacchio D., Wang L., Craig J.M., Jones P.L., Sif S., El-Osta A. Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat. Genet. 2005, 37:254-264.
13. Ballas N., Grunseich C., Lu D.D., Speh J.C., Mandel G. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 2005, 121:645-657.
14. Baker S.A., Chen L., Wilkins A.D., Yu P., Lichtarge O., Zoghbi H.Y. An AT-hook domain in MeCP2 determines the clinical course of Rett syndrome and related disorders. Cell 2013, 152:984-996.
15. Mellen M., Ayata P., Dewell S., Kriaucionis S., Heintz N. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 2012, 151:1417-1430.
16. Skene P.J., Illingworth R.S., Webb S., Kerr A.R., James K.D., Turner D.J., Andrews R., Bird A.P. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol. Cell 2010, 37:457-468.
17. Nawaz Z., Lonard D.M., Smith C.L., Lev-Lehman E., Tsai S.Y., Tsai M.J., O'Malley B.W. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol. Cell. Biol. 1999, 19:1182-1189.
18. Lim J., Hao T., Shaw C., Patel A.J., Szabo G., Rual J.F., Fisk C.J., Li N., Smolyar A., Hill D.E., Barabasi A.L., Vidal M., Zoghbi H.Y. A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell 2006, 125:801-814.
19. Warming S., Costantino N., Court D.L., Jenkins N.A., Copeland N.G. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 2005, 33:e36.
20. Collins A.L., Levenson J.M., Vilaythong A.P., Richman R., Armstrong D.L., Noebels J.L., David Sweatt J., Zoghbi H.Y. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum. Mol. Genet. 2004, 13:2679-2689.
21. Jiang Y.H., Armstrong D., Albrecht U., Atkins C.M., Noebels J.L., Eichele G., Sweatt J.D., Beaudet A.L. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 1998, 21:799-811.
22. Ju H., Kokubu H., Todd T.W., Kahle J.J., Kim S., Richman R., Chirala K., Orr H.T., Zoghbi H.Y., Lim J. Polyglutamine disease toxicity is regulated by nemo-like kinase in spinocerebellar ataxia type 1. J. Neurosci. 2013, 33:9328-9336.
23. Kao W.H., Beaudenon S.L., Talis A.L., Huibregtse J.M., Howley P.M. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase. J. Virol. 2000, 74:6408-6417.
24. Wu Y., Bolduc F.V., Bell K., Tully T., Fang Y., Sehgal A., Fischer J.A. A Drosophila model for Angelman syndrome. Proc. Natl. Acad. Sci. USA 2008, 105:12399-12404.
25. Cukier H.N., Perez A.M., Collins A.L., Zhou Z., Zoghbi H.Y., Botas J. Genetic modifiers of MeCP2 function in Drosophila. PLoS Genet. 2008, 4:e1000179.
26. Low D., Chen K.S. Genome-wide gene expression profiling of the Angelman syndrome mice with Ube3a mutation. Eur. J. Hum. Genet. 2010, 18:1228-1235.
27. Kuhnle S., Mothes B., Matentzoglu K., Scheffner M. Role of the ubiquitin ligase E6AP/UBE3A in controlling levels of the synaptic protein Arc. Proc. Natl. Acad. Sci. USA 2013, 110:8888-8893.
28. Zaaroor-Regev D., de Bie P., Scheffner M., Noy T., Shemer R., Heled M., Stein I., Pikarsky E., Ciechanover A. Regulation of the polycomb protein Ring1B by self-ubiquitination or by E6-AP may have implications to the pathogenesis of Angelman syndrome. Proc. Natl. Acad. Sci. USA 2010, 107:6788-6793.
29. Margolis S.S., Salogiannis J., Lipton D.M., Mandel-Brehm C., Wills Z.P., Mardinly A.R., Hu L., Greer P.L., Bikoff J.B., Ho H.Y., Soskis M.J., Sahin M., Greenberg M.E. EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a developmental brake on excitatory synapse formation. Cell 2010, 143:442-455.
30. Greer P.L., Hanayama R., Bloodgood B.L., Mardinly A.R., Lipton D.M., Flavell S.W., Kim T.K., Griffith E.C., Waldon Z., Maehr R., Ploegh H.L., Chowdhury S., Worley P.F., Steen J., Greenberg M.E. The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc. Cell 2010, 140:704-716.